On Tuesday, Pfizer Inc. PFE reported fourth-quarter adjusted EPS of 63 cents, in comparison with 10 cents a 12 months in the past, beating the consensus of 47 cents.
The U.S. drugmaker reported gross sales of $17.76 billion, up 22% year-over-year (up 21% operationally), beating the consensus of $17.40 billion.
The rise displays a one-time, non-cash Paxlovid income reversal of $3.5 billion recorded in fourth-quarter 2023 and, to a lesser extent, progress contributions in fourth-quarter 2024 from the legacy Seagen portfolio, the Vyndaqel household, larger Paxlovid gross sales year-over-year, larger gross sales in a number of different merchandise throughout all classes, and a positive affect of overseas trade.
Excluding contributions from Paxlovid and Comirnaty, fourth-quarter 2024 revenues totaled $13.7 billion, a rise of $1.3 billion, or 11%, operationally in contrast with the prior-year quarter.
This was primarily pushed by legacy Seagen, Vyndaqel household, Eliquis, Nurtec ODT/Vydura, and Xtandi, partially offset by decrease revenues for Abrysvo, Xeljanz and Oncology biosimilars.
Learn Subsequent: Is Huge Pharma About To Win? Goldman Sachs Weighs In On 340B And Medicaid Shifts
Fourth-quarter 2024 Comirnaty revenues of $3.83 billion decreased $2.0 billion, or 38%, operationally in contrast with the prior-year quarter, pushed primarily by fewer COVID-19 vaccinations globally and decrease contracted doses.
Fourth-quarter 2024 Paxlovid revenues of $727 million elevated $3.9 billion operationally in contrast with $(3.1) billion of revenues recorded within the prior-year quarter, primarily pushed by the transition to conventional business market gross sales within the U.S., together with a one-time, non-cash income reversal of $3.5 billion recorded in fourth-quarter 2023.
Vyndaqel household medicine generated sales of $1.55 billion, up 60%. Eliquis, a blood thinner drug, generated gross sales of $1.83 billion, up 14%.
World revenues of $915 million from legacy Seagen in contrast with $132 million in fourth-quarter 2023 following the completion of the acquisition in mid-December 2023.
Nurtec ODT/Vydura gross sales jumped 39% to $392 million. Prevnar household pneumococcal vaccine gross sales dipped 4% to $1.56 billion, and Abrysvo RSV vaccine gross sales slumped 62% to $198 million.
Steering: Pfizer reaffirms 2025 revenues of $61 billion-$64 billion in comparison with consensus of $63.025 billion.
The corporate anticipates adjusted EPS of $2.80-$3.00 in comparison with consensus of $2.94.
Value Motion: On the final test on Tuesday, PFE inventory was up 1.87% at $26.69 through the premarket session.
Learn Subsequent:
Picture by way of Shutterstock
Overview Score:
Speculative
Market Information and Information delivered to you by Benzinga APIs
© 2025 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
